These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 20451686

  • 1. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Am J Cardiol; 2010 May 15; 105(10):1409-12. PubMed ID: 20451686
    [Abstract] [Full Text] [Related]

  • 2. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 15; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.
    Am J Cardiol; 2010 Feb 15; 105(4):487-94. PubMed ID: 20152243
    [Abstract] [Full Text] [Related]

  • 5. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Bays HE, Maki KC, Doyle RT, Stein E.
    Postgrad Med; 2009 Sep 15; 121(5):145-50. PubMed ID: 19820283
    [Abstract] [Full Text] [Related]

  • 6. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.
    J Cardiovasc Pharmacol; 2009 Sep 15; 54(3):196-203. PubMed ID: 19597368
    [Abstract] [Full Text] [Related]

  • 7. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 8. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 9. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
    Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.
    Curr Med Res Opin; 2010 Apr 15; 26(4):907-15. PubMed ID: 20156032
    [Abstract] [Full Text] [Related]

  • 10. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Apr 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 11. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 15; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 12. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
    Feldman T, Koren M, Insull W, McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y.
    Am J Cardiol; 2004 Jun 15; 93(12):1481-6. PubMed ID: 15194017
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 14. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Sep 15; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 15. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Maki KC, Lawless AL, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW.
    J Cardiovasc Pharmacol; 2011 Apr 15; 57(4):489-94. PubMed ID: 21297494
    [Abstract] [Full Text] [Related]

  • 16. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ.
    Am J Cardiol; 2010 May 15; 105(10):1413-9. PubMed ID: 20451687
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D, Morgan C, Rigby RJ, Westhuyzen J.
    Am J Kidney Dis; 2002 Feb 15; 39(2):283-90. PubMed ID: 11840368
    [Abstract] [Full Text] [Related]

  • 18. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.
    Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS.
    J Clin Lipidol; 2009 Feb 15; 3(1):33-8. PubMed ID: 21291786
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ.
    Am J Cardiol; 2010 Jan 01; 105(1):69-76. PubMed ID: 20102893
    [Abstract] [Full Text] [Related]

  • 20. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 01; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.